Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177108 · ClinicalTrials.gov registry record · Phase 3
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT04177108 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 242 participants.
The verdict
NCT04177108, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
Interventions
- DRUG Atezolizumab
- DRUG Ipatasertib
- DRUG Paclitaxel
- DRUG Placebo for Atezolizumab
- DRUG Placebo for Ipatasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2019-11-25 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177108
The ClinicalTrials.gov registry entry for NCT04177108 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04177108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04177108 about?
NCT04177108 is a clinical study titled "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer". This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
What is the current status of trial NCT04177108?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2019-11-25. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04177108?
The interventions under investigation include: Atezolizumab (DRUG), Ipatasertib (DRUG), Paclitaxel (DRUG), Placebo for Atezolizumab (DRUG), Placebo for Ipatasertib (DRUG).
Who is sponsoring clinical trial NCT04177108?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.